Eugene Lutsenko, Phd, Mba Email and Phone Number

Execution of alternative investment strategies in derivatives such as futures, options on futures, and options on ETFs. Development of short-term quantitative trading strategies in options on individual stocks during binary events, such as earning announcements.

Private Equity Assignments:• A $500 million private placement for a $4.4 billion pharmaceutical royalties firm– Analysis of the Company’s strategy, industry positioning and financials during the preparation of marketing materials• Evaluation of an opportunity to invest $2 million in a healthcare venture fund– Due diligence on each portfolio company, including financial, operational and strategic analyses, to determine valuation and exit alternativesInvestment… Show more Private Equity Assignments:• A $500 million private placement for a $4.4 billion pharmaceutical royalties firm– Analysis of the Company’s strategy, industry positioning and financials during the preparation of marketing materials• Evaluation of an opportunity to invest $2 million in a healthcare venture fund– Due diligence on each portfolio company, including financial, operational and strategic analyses, to determine valuation and exit alternativesInvestment Banking Mandates:• Acquisition of a $300 million in revenues business unit of a publicly traded consumer goods company– Financial modeling to analyze potential structuring alternatives and associated accretion / dilution scenarios– On-site due diligence of the target company to evaluate its operational efficiencies• Sell-side advisory for a private company on its sale to a $1 billion special purpose acquisition company (SPAC)– Valuation of SPAC’s units comprised of warrants and shares Show less

• Evaluated various healthcare services companies for a potential acquisition by a strategic buyer– Forecasted industry trends, target companies’ financial and operational data and prepared a “pitch book”– Performed comparable transaction and trading analyses to maintain M&A financial models

• Identified a Phase II therapeutic compound and proceeded with its in-licensing from a Japan-based pharmaceutical company • Utilized DCF and qualitative approaches to assess potential market value of therapeutic compounds available for acquisition• Participated in scientific conferences; interviewed researchers and management of companies to find acquisition candidates

• Raised over $350 thousand in financing from US health organizations and private donors• Managed a five-member team of research scientists in daily operations; team established a new direction in cancer research• Published two articles as a first author in peer-reviewed academic journals